Purified Nisin Intramammary Treatment for Mastitis
Our intramammary treatment for subclinical mastitis in lactating cows utilizes a bacteriocin – Nisin – to treat infections without the use of traditional antibiotics; thereby reducing the amount of antibiotics in the human food chain.
Mastitis is the most costly and common disease affecting the dairy industry inflicting approximately $2 billion in economic harm per year. The disease diminishes the saleable quantity and overall value of milk, in addition to causing other herd health and productivity losses. While the benefit of treating clinical mastitis is widely known, subclinical mastitis (those cases where cows have infected udders, but still produce saleable milk) is associated with its own significant economic losses and is recognized as a substantial contributor to clinical mastitis cases.
There is a growing awareness of the cascade of adverse events and conditions associated with subclinical mastitis, including reduced or foregone milk quality premiums, lower milk production, shorter shelf life for fluid milk, lower yields and less flavor for cheese, higher rates of clinical mastitis, lower conception rates, increased abortions and increased cull rates.